COVID-19, the abbreviation for the global outbreak of the novel coronavirus, is an infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Since its initial outbreak in Wuhan, Hubei Province, China, at the end of 2019, COVID-19 has rapidly spread to all corners of the world, becoming one of the most serious public health challenges of the 21st century. As of the latest data, COVID-19 has infected tens of millions of people, resulting in millions of deaths and causing significant impacts on the global economy and society.

The outbreak of COVID-19 has triggered global attention and panic due to its high infectivity and potential lethality. This coronavirus is transmitted through respiratory droplets, facilitating its rapid spread among individuals. At the same time, COVID-19 has a relatively long incubation period, allowing carriers to spread the disease without exhibiting obvious symptoms, thereby increasing the challenges in epidemic prevention and control.

During its global pandemic, COVID-19 has imposed a tremendous burden on the socioeconomic and healthcare systems. Countries and regions have implemented various measures to combat the outbreak, including lockdowns, social distancing, travel restrictions, and large-scale testing. Nevertheless, COVID-19 continues to exert enormous pressure on the global public health system and medical resources, posing a severe threat to people's lives and well-being.

There are different opinions and controversies regarding whether COVID-19 should be defined as a super-virus. Super-virus typically refers to a virus with high infectivity, pathogenicity, and global epidemic potential. Although COVID-19 exhibits certain characteristics of infectivity and global spread, its morbidity and mortality rates are relatively low. Compared to some historically significant viral pandemics, its impact is not yet sufficient to be classified as a super-virus.

This article will explore whether COVID-19 possesses the characteristics of a super-virus by analyzing information on the disease's epidemiology, transmission modes, classification by the World Health Organization (WHO), and comparisons with other viruses.

1 Definitions and Characteristics

1.1 Definition and characteristics of super-viruses

A super-virus refers to a virus that possesses exceptionally high infectivity, pathogenicity, and global epidemic potential. These viruses cause severe diseases in humans and animals and have the characteristics of rapid transmission and wide-ranging impact. Super-viruses typically exhibit the following features.

High infectivity: Super-viruses can rapidly spread to a large number of people through airborne droplets, direct contact, or transmission via intermediaries. They have strong transmissibility and can infect a significant number of individuals within a short period.

High pathogenicity: Diseases caused by super-viruses often have a high morbidity and mortality rate. These viruses can result in severe symptoms and complications, posing a significant threat to the health of infected individuals.

Global epidemic potential: Super-viruses have the potential for global spread, crossing borders and geographical barriers, rapidly disseminating to different regions within a short period, leading to widespread outbreaks.

1.2 Comparison of known super-virus examples

Here is a brief introduction to some known examples of super-viruses, presented in a tabular form for better understanding of their characteristics and impacts (Table 1).

The examples mentioned above represent only a small fraction of known super-viruses. These viruses differ in terms of their transmissibility, pathogenicity, and global epidemic potential, but they all possess certain characteristics of super-viruses.

1.3 Transmissibility, pathogenicity, and global epidemic characteristics of COVID-19

Transmissibility: According to data from the World Health Organization (WHO), COVID-19 exhibits high transmissibility. It spreads through respiratory droplets, which can be transmitted to others when an infected individual coughs, sneezes, or has close contact. Additionally, the virus can also spread through contact with contaminated surfaces.

Pathogenicity: The pathogenicity of COVID-19 varies among individuals. Most infected individuals experience mild to moderate symptoms, including fever, cough, fatigue, etc. However, some individuals may develop severe symptoms such as difficulty breathing and pneumonia, which can lead to death. Older adults and individuals with underlying chronic conditions are particularly susceptible to severe impacts.

Global epidemic: Since its initial appearance in 2019, COVID-19 has rapidly spread globally. According to reports from the World Health Organization, millions of people have been infected with COVID-19 to date, and countries and regions worldwide have been affected. This global epidemic indicates that COVID-19 possesses characteristics of a super-virus.

2 Characteristics of COVID-19

2.1 Description of COVID-19

The novel coronavirus COVID-19 is a virus belonging to the coronavirus family and has the following basic characteristics:

Pathogen: COVID-19 is caused by a single-stranded positive-sense RNA virus and belongs to the subgenus β-coronavirus.

Symptoms: COVID-19 primarily manifests as a respiratory illness. The most common symptoms include fever, cough, fatigue, and difficulty breathing. Some infected individuals may experience mild symptoms, while others may develop severe symptoms or even die.

Incubation period: The incubation period of COVID-19 is typically 2~14 days, which means it may take some time after infection for noticeable symptoms to appear.

2.2 Modes of transmission and severity modes of transmission

Modes of transmission: COVID-19 mainly spreads through respiratory droplets. When an infected individual coughs, sneezes, or has close contact with others, the virus can be transmitted through respiratory droplets. Additionally, touching surfaces contaminated by the virus can also lead to infection. Recent research also suggests the potential role of aerosol transmission in specific environments.

Severity: The severity of COVID-19 varies among individuals. Most infected individuals experience mild to moderate symptoms and can recover on their own. However, older adults and individuals with underlying chronic diseases are more prone to develop severe cases that require hospital treatment and monitoring.

2.3 Global pandemic data and statistics

As of now, COVID-19 has caused a severe global epidemic. Here are some popular figures and statistics from around the world.

Number of infections: According to the World Health Organization, as of May 17, 2023, there have been over 160 million confirmed COVID-19 cases worldwide.

Number of deaths: COVID-19 has caused a significant number of deaths. According to the World Health Organization, as of May 17, 2023, the global death toll from COVID-19 has exceeded 3.4 million.

Affected countries and regions: COVID-19 has impacted countries and regions worldwide, particularly densely populated cities and nations. Some of the most severely affected countries include the United States, India, Brazil, Russia, and France, among others.

Infection and fatality rates: The infection and fatality rates of COVID-19 vary by region and population group. The infection rates in different countries and regions are influenced by factors such as testing rates, prevention and control measures, and population density. Fatality rates depend on factors such as the burden on healthcare systems, availability of medical resources, and the overall health of the population.

Vaccination efforts: Various COVID-19 vaccines have been developed and deployed globally, leading to large-scale vaccination campaigns. Vaccination significantly reduces the risk of infection and severe illness and plays a crucial role in controlling the pandemic.

It is important to note that the above data and statistics are based on the latest reliable sources and may change over time. The situation of the COVID-19 pandemic continues to evolve, emphasizing the need for ongoing monitoring and preventive measures.

3 Comparative Analysis

3.1 Comparing the characteristics of COVID-19 and super viruses

When comparing the characteristics of COVID-19 and super viruses, a comparison can be made using descriptive text and tables. Here is a comparison between COVID-19 and some known super viruses (Table 2).

3.2 Analyzing the infectiousness, pathogenicity, and global spread of COVID-19

When analyzing the infectiousness, pathogenicity, and global spread of COVID-19, a comparison can be made using descriptive text and tables. Here is a comparison between COVID-19 and some known super viruses (Table 3).

3.3 Comparing the similarities and differences between COVID-19 and known super viruses

When comparing the similarities and differences between COVID-19 and known super viruses, a comparison can be made using descriptive text and tables. Here is a comparison between COVID-19 and some known super viruses (Table 4).

Through the above comparisons, we can see that COVID-19 shares some similarities and differences in terms of characteristics, infectivity, pathogenicity, and global spread compared to known super viruses. COVID-19 exhibits high infectivity and global spread, but comparatively lower pathogenicity. Additionally, in contrast to some super viruses with high fatality rates and prominent symptoms, COVID-19 tends to result in milder symptoms for most infected individuals.

Please note that the data provided in the above tables are for comparative purposes and the actual data may vary over time and across regions. Furthermore, the definition and characteristics of super viruses are still evolving and under ongoing scientific research, so further scientific investigation and assessment are needed to determine if COVID-19 qualifies as a super virus.

4 Scientific Community Perspectives

4.1 Overview of the scientific community's views on defining

COVID-19 as a Super Virus There are varying opinions within the scientific community regarding defining COVID-19 as a super virus. Despite the significant global impact of COVID-19 and its characteristics of infectivity and global spread, whether it meets the strict definition of a super virus remains subject to further discussion and evaluation.

4.2 Quoting expert opinions and research papers

Many experts and scientists have expressed their views on whether COVID-19 can be classified as a super virus. Based on some research papers and expert opinions, here are some typical viewpoints.

Some experts argue that COVID-19 exhibits certain characteristics of a super virus. According to their perspective, COVID-19 has spread widely on a global scale, infecting a large number of individuals, and possesses a certain level of pathogenicity and transmissibility. These features make COVID-19 one of the most significant public health challenges of our time.

Other experts maintain a more cautious stance, suggesting that although COVID-19 demonstrates global pandemic characteristics, its infectivity and pathogenicity are relatively low, creating a gap when compared to known super viruses. According to their viewpoint, super viruses should exhibit higher infectivity, pathogenicity, and fatality rates.

4.3 Exploring academic disagreements and different standpoints

Within the academic community, there exist disagreements and different standpoints regarding the classification of COVID-19 as a super virus. This divergence primarily arises from inconsistent interpretations of the strict definition and characteristics of super viruses. Some scholars argue that the degree of infectivity and global spread are crucial indicators for determining a super virus, while others believe that super viruses should possess higher pathogenicity and fatality rates.

Furthermore, ongoing research and evaluation of COVID-19 are being conducted within the scientific community to gain a more comprehensive and objective understanding of its characteristics and impact. Over time, we can expect more scientific studies and expert perspectives to emerge, providing a more accurate assessment of whether COVID-19 aligns with the definition of a super virus.

It is important to note that the discussion surrounding whether COVID-19 qualifies as a super virus is an evolving field, and the scientific community has yet to reach a unified conclusion. Therefore, it is crucial to stay informed about the latest research findings and academic discussions to gain a better understanding of COVID-19's characteristics and its relationship to super viruses.

5 Challenges and Limitations

5.1 Challenges and limitations in identifying the argumentation process

In discussing whether COVID-19 is a super virus, there are some challenges and limitations that need to be recognized and considered. Some of these challenges and limitations include:

Uncertainty of data: In the research process, the accuracy and completeness of data are important issues. As COVID-19 is a newly emerged virus, data regarding its characteristics and impacts may still be accumulating and updating, leading to some degree of uncertainty.

Reliability and credibility of information: When conducting research and discussions, we need to rely on reliable information sources and authoritative views. However, research and understanding of COVID-19 are still ongoing, and there may be inconsistent views and research results, which may affect our judgment on whether it is a super virus.

5.2 Discussion of the problem of lack of scientific consensus and definition ambiguity

In the discussion of defining COVID-19 as a super virus, the lack of scientific consensus and definition ambiguity is also a challenge. There is no clear standard for defining a super virus, and different scholars and institutions may have different interpretations and understandings of its characteristics and standards. This ambiguity may lead to subjectivity and controversy in evaluating whether COVID-19 is a super virus.

5.3 Mentioning the limitations of ongoing research and understanding of COVID-19

As a newly emerged virus, COVID-19 is still being researched and understood. Our understanding of its characteristics, transmission routes, severity, and other aspects is still gradually accumulating and updating. This means that we may not have obtained comprehensive and accurate enough information to fully evaluate whether it meets the definition of a super virus.

In summary, there are some challenges and limitations in the argumentation process of defining COVID-19 as a super virus, such as the uncertainty of data, the reliability and credibility of information, and the lack of scientific consensus and definition ambiguity. Moreover, as COVID-19 is still being researched and understood, we need to continuously pay attention to the latest scientific achievements and views in order to obtain more accurate evaluations.

6 Integrated Analysis and Personal Opinion

6.1 Analysis of the evidence and viewpoints presented

Through the preceding arguments, we have discussed various viewpoints and pieces of evidence regarding whether COVID-19 can be classified as a super virus. We have examined the characteristics of COVID-19, including its infectivity, pathogenicity, and global spread, and compared them with known super viruses. We have also outlined the perspectives within the scientific community and mentioned some expert opinions and research papers.

6.2 Summarizing the controversy surrounding defining

COVID-19 as a Super Virus Based on our discussion and integrated analysis, there is controversy and uncertainty regarding whether COVID-19 can be defined as a super virus. On one hand, COVID-19 exhibits some characteristics of super viruses, such as high infectivity, severe disease cases, and a global pandemic trend. Furthermore, the speed of its transmission and its impact have garnered significant attention when compared to other known super viruses.

However, we must also recognize that the definition of a super virus lacks clear criteria, and different scholars and organizations have different interpretations of its characteristics and standards. Additionally, COVID-19 is a newly emerged virus, and our understanding of it is still accumulating and evolving. Therefore, at this stage, we may not be able to definitively conclude that COVID-19 should be strictly defined as a super virus.

6.3 Presenting personal opinion and explaining the position

Based on my comprehensive analysis of the available evidence and discussions, I believe that COVID-19 exhibits certain characteristics of a super virus, particularly its high infectivity and global pandemic trend. However, due to the ambiguous and non-consensual definition of a super virus, as well as the ongoing research and understanding of COVID-19, I think it is currently not possible to definitively define COVID-19 as a super virus.

I support continued scientific research to gain a deeper understanding of the characteristics and impact of COVID-19 in order to assess its position within the realm of super viruses more accurately. This requires ongoing attention to the latest scientific findings and viewpoints, strengthening international cooperation, and enhancing efforts in global epidemic prevention and control.

In conclusion, whether COVID-19 can be defined as a super virus is a complex and controversial question.

7 Conclusion

7.1 Restatement of the topic and key points

This article explores the question of whether "COVID-19, the novel coronavirus, can be defined as a super virus." We have analyzed the characteristics, transmission pathways, and global spread of COVID-19 and compared them to known super viruses. We have also examined the viewpoints within the scientific community, expert opinions, and research papers to provide an integrated analysis of whether COVID-19 fits the definition of a super virus.

7.2 Summary of key findings from the discussion

Through the analysis of the features and spread of COVID-19, we have found that COVID-19 exhibits some characteristics of a super virus, such as high infectivity, global pandemic trend, and severe impact on public health and the economy. However, due to the ambiguity and lack of consensus in the definition of a super virus, as well as the ongoing research and understanding of COVID-19, it is currently not possible to definitively define COVID-19 as a super virus.

7.3 Emphasizing the complexity of the debate and the importance of further research

The discussion presented in this article highlights the controversy and complexity surrounding the classification of COVID-19 as a super virus. The definition of a super virus involves multiple factors, including infectivity, pathogenicity, global spread, etc., and different scholars and organizations have different perspectives on its criteria and characteristics. Additionally, COVID-19 being a newly emerged virus means our understanding of it is still evolving and accumulating.

Therefore, to accurately assess whether COVID-19 fits the definition of a super virus, continued scientific research and data collection are needed. Strengthening international cooperation, sharing information and experiences, is crucial. Simultaneously, enhancing efforts in global epidemic prevention and control, including vaccination, public health measures, and health education, are key to addressing COVID-19 and future pandemics.

In conclusion, the discussion above demonstrates that there is still debate regarding whether COVID-19 has reached the level of a super virus. We must continue to pay attention to the latest scientific research, strengthen global cooperation, and better understand and address the challenges posed by COVID-19. Through ongoing research and collaborative efforts, we will be better prepared to handle future epidemic threats and safeguard the health and well-being of the global population.

Author’s contributions

Zhang Jie, the lead researcher of this study, was responsible for conducting literature review, data analysis, and independently completing the initial draft and revisions of the paper. The author has read and agreed to the final version of the manuscript.

References

Agyeman A.A., Chin K.L., Landersdorfer C.B., Liew D., and Ofori-Asenso R., 2020, Smell and taste dysfunction in patients with COVID-19: A systematic review and meta-analysis, Mayo Clin. Proc., 95(8): 1621-1631.

https://doi.org/10.1016/j.mayocp.2020.05.030

Cascella M., Rajnik M., Cuomo A., Dulebohn S.C., and Napoli R.D., 2020, Features, evaluation and treatment coronavirus (COVID-19), StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32150360

Centers for Disease Control and Prevention, 2021, Clinical questions about COVID-19: Questions and Answers.

Centers for Disease Control and Prevention, 2021, Scientific brief: SARS-CoV-2 Transmission.

Communicable Diseases Network Australia, 2020, Coronavirus disease 2019 (COVID-19): CDNA National Guidelines for Public Health Units.

Communicable Diseases Network Australia, 2021, Coronavirus disease 2019 (COVID-19) - CDNA Guidelines for Public Health Units.

European Centre for Disease Prevention and Control, 2021, Transmission of COVID-19.

Gorzalski A.J., Tian H., Laverdure C., Morzunov S., Verma S.C., VanHooser S., and Pandori M.W., 2020, High-throughput transcription-mediated amplification on the hologic panther is a highly sensitive method of detection for SARS-CoV-2, J. Clin. Virol., 129: 104501.

https://doi.org/10.1016/j.jcv.2020.104501

GOV.UK., COVID-19: epidemiology, virology and clinical features.

Grant M.C., Geoghegan L., Arbyn M., Mohammed Z., McGuinness L., Clarke E.L., and Wade R.G., 2020, The prevalence of symptoms in 24 410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries, PLoS ONE, 15(6): e0234765.

https://doi.org/10.1371/journal.pone.0234765

He X., Lau E.H.Y., Wu P., Deng X., Wang J., Hao X., Lau Y.C., Wong J.Y., Guan Y., Tan X., Mo X., Chen Y., Liao B., Chen W., Hu F., Zhang Q., Zhong M., Wu Y., Zhao L., Zhang F., Cowling B.J., Li F., and Leung G.M., 2020, Temporal dynamics in viral shedding and transmissibility of COVID-19, Nat. Med., 26(5): 672-675.

https://doi.org/10.1038/s41591-020-0869-5

Heymann D.L., Shindo N., and WHO Scientific and Technical Advisory Group for Infectious Hazards, 2020, COVID-19: what is next for public health ?, Lancet., 395(10224): 542-545.

https://doi.org/10.1016/S0140-6736(20)30374-3

Hui D.S., Azhar E.I., Madani T.A., Ntoumi F., Kock R., Dar O., Ippolito G., Mchugh T.D., Memish Z.A., Drosten C., Zumla A., and Petersen E., 2020, The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China, Int. J. Infect. Dis., 91: 264-266.

https://doi.org/10.1016/j.ijid.2020.01.009

Islam M.A., Alam S.S., Kundu S., Hossan T., Kamal M.A., and Cavestro C., 2020, Prevalence of headache in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 14 275 patients, Front. Neurol., 11: 562634.

https://doi.org/10.3389/fneur.2020.562634

Islam M.A., Kundu S., Alam S.S., Hossan T., Kamal M.A., and Hassan R., 2021, Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients, PLoS ONE, 16 (4): e0249788.

https://doi.org/10.1371/journal.pone.0249788

Li C., Zhao C., Bao J., Tang B., Wang Y., and Gu B., 2020, Laboratory diagnosis of coronavirus disease-2019 (COVID-19), Clin. Chim. Acta, 510: 35-46.

https://doi.org/10.1016/j.cca.2020.06.045

Long B., Brady W.J., Koyfman A., and Gottlieb M., 2020, Cardiovascular complications in COVID-19, Am. J. Emerg. Med., 38(7): 1504-1507.

https://doi.org/10.1016/j.ajem.2020.04.048

Meyerowitz E.A., Richterman A., Gandhi R.T., and Sax P.E., 2021, Transmission of SARS-CoV-2: A review of viral, host, and environmental factors, Ann. Intern. Med., 174(1): 69-79.

https://doi.org/10.7326/M20-5008

Miller S.L., Nazaroff W.W., Jimenez J.L., Boerstra A., Buonanno G., Dancer S.J., Kurnitski J., Marr L.C., Morawska L., and Noakes C., 2021, Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event, Indoor Air, 31(2): 314-323.

https://doi.org/10.1111/ina.12751

Mittal R., Ni R., and Seo J., 2020, The flow physics of COVID-19, J. Fluid Mech., 894: F2.

https://doi.org/10.1017/jfm.2020.330

Morawska L., Allen J., Bahnfleth W., Bluyssen P.M., Boerstra A., Buonanno G., Cao J., Dancer S.J., Floto A., Franchimon F., Greenhalgh T., Haworth C., Hogeling J., Isaxon C., Jimenez J.L., Kurnitski J., Li Y., Loomans M., Marks G., Marr L.C., Mazzarella L., Melikov A.K., Miller S., Milton D.K., Nazaroff W., Nielsen P.V., Noakes C., Peccia J., Prather K., Querol X., Sekhar C., Seppänen O., Tanabe S.I., Tang J.W., Tellier R., Tham K.W., Wargocki P., Wierzbicka A., and Yao M., 2021, A paradigm shift to combat indoor respiratory infection, Science, 372(6543): 689-691.

https://doi.org/10.1126/science.abg2025

Murthy S., Gomersall C.D., and Fowler R.A., 2020, Care for critically Ill patients with COVID-19, JAMA, 323(15): 1499-1500.

https://doi.org/10.1001/jama.2020.3633

Oran D.P., and Topol E.J., 2021, The proportion of SARS-CoV-2 infections that are asymptomatic: A systematic review, Ann. Intern. Med., 174(5): 655-662.

https://doi.org/10.7326/M20-6976

Public Health Agency of Canada, 2020, COVID-19: Main modes of transmission.

Puntmann V.O., Carerj M.L., Wieters I., Fahim M., Arendt C., Hoffmann J., Shchendrygina A., Escher F., Vasa-Nicotera M., Zeiher A.M., Vehreschild M., and Nagel E., 2020, Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19), JAMA Cardiol., 5(11): 1265-1273.

https://doi.org/10.1001/jamacardio.2020.3557

Romiti G.F., Corica B., Lip G.Y.H., and Proietti M., 2021, Prevalence and impact of atrial fibrillation in hospitalized patients with COVID-19: A systematic review and meta-analysis, J. Clin. Med., 10(11): 2490.

https://doi.org/10.3390/jcm10112490

Saniasiaya J., Islam M.A., and Abdullah B., 2021, Prevalence and characteristics of taste disorders in cases of COVID-19: A meta-analysis of 29 349 patients, Otolaryngol. Head Neck Surg., 165(1): 33-42.

https://doi.org/10.1177/0194599820981018

Saniasiaya J., Islam M.A., and Abdullah B., 2021, Prevalence of olfactory dysfunction in coronavirus disease 2019 (COVID-19): A meta-analysis of 27 492 patients, Laryngoscope, 131(4): 865-878.

https://doi.org/10.1002/lary.29286

Stadnytskyi V., Bax C.E., Bax A., and Anfinrud P., 2020, The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission, Proc. Natl. Acad. Sci. USA, 117(22): 11875-11877.

https://doi.org/10.1073/pnas.2006874117

Tang J.W., Marr L.C., Li Y., and Dancer S.J., 2021, Covid-19 has redefined airborne transmission, BMJ, 373: n913.

https://doi.org/10.1136/bmj.n913

Wen W., Zhang H., Zhou M., Cheng Y., Ye L., Chen J., Wang M., and Feng Z., 2020, Arrhythmia in patients with severe coronavirus disease (COVID-19): A meta-analysis, Eur. Rev. Med. Pharmacol. Sci., 24(21): 11395-11401.

World Health Organization, 2021, Coronavirus disease (COVID-19): How is it transmitted?